Karen L Reckamp

List of Publications by Year
in descending order

155 papers	16,895 citations	47 h-index	127 g-index
		47006	14759
158 all docs	158 docs citations	158 times ranked	21071 citing authors

#	Article	IF	Citations
1	Nivolumab versus Docetaxel in Advanced Squamous-Cell Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2015, 373, 123-135.	27.0	7,261
2	Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Nonâ€“Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.6	726
3	Prostaglandin E2 Induces FOXP3 Gene Expression and T Regulatory Cell Function in Human CD4+ T Cells. Journal of Immunology, 2005, 175, 1483-1490.	0.8	543
4	Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinaseâ€“Positive Nonâ€“Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. Journal of Clinical Oncology, 2017, 35, 2490-2498.	1.6	506
5	Efficacy of Selpercatinib in RET Fusionâ€“Positive Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2020, 383, 813-824.	27.0	505
6	Tumor Cyclooxygenase-2/Prostaglandin E2â€“Dependent Promotion of FOXP3 Expression and CD4+CD25+ T Regulatory Cell Activities in Lung Cancer. Cancer Research, 2005, 65, 5211-5220.	0.9	452
7	Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Nonâ€“small Cell Lung Cancer. Clinical Cancer Research, 2019, 25, 4691-4700.	7.0	401
8	NCCN Guidelines Insights: Nonâ€“Small Cell Lung Cancer, Version 5.2018. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 807-821.	4.9	394
9	NCCN Guidelines Insights: Nonâ€“Small Cell Lung Cancer, Version 4.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 255-264.	4.9	335
10	Nonâ€“Small Cell Lung Cancer, Version 6.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 515-524.	4.9	323
11	Amivantamab in EGFR Exon 20 Insertionâ€“Mutated Nonâ€“Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. Journal of Clinical Oncology, 2021, 39, 3391-3402.	1.6	320
12	A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma. Journal of Thoracic Oncology, 2016, 11, 1690-1700.	1.1	256
13	Prostaglandin E2 Activates Mitogen-Activated Protein Kinase/Erk Pathway Signaling and Cell Proliferation in Nonâ€“Small Cell Lung Cancer Cells in an Epidermal Growth Factor Receptorâ€“Independent Manner. Cancer Research, 2005, 65, 6275-6281.	0.9	207
14	Akt inhibitors in clinical development for the treatment of cancer. Expert Opinion on Investigational Drugs, 2010, 19, 1355-1366.	4.1	202
15	Interdisciplinary Palliative Care for Patients With Lung Cancer. Journal of Pain and Symptom Management, 2015, 50, 758-767.	1.2	155
16	Phase I Trial of Intratumoral Injection ofCCL21Geneâ€“Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration. Clinical Cancer Research, 2017, 23, 4556-4568.	7.0	149
17	Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Molecular Cancer, 2006, 5, 56.	19.2	147
18	Ensartinib (X-396) in ALK-Positive Nonâ€“Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. Clinical Cancer Research, 2018, 24, 2771-2779.	7.0	141

#	Article	IF	Citations
19	The Role of CXCR2/CXCR2 Ligand Biological Axis in Renal Cell Carcinoma. Journal of Immunology, 2005, 175, 5351-5357.	0.8	133
20	Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 1901-1911.	1.1	127
21	A phase 2 trial of dacomitinib (PFâ€00299804), an oral, irreversible panâ€HER (human epidermal growth) Tj ETQq1 1 0.784314 rgBT /O prior chemotherapy and erlotinib. Cancer, 2014, 120, 1145-1154.	4.1	125
22	Identification of Five Candidate Lung Cancer Biomarkers by Proteomics Analysis of Conditioned Media of Four Lung Cancer Cell Lines. Molecular and Cellular Proteomics, 2009, 8, 2746-2758.	3.8	124
23	Targeting Stat3 in the Myeloid Compartment Drastically Improves the In vivo Antitumor Functions of Adoptively Transferred T Cells. Cancer Research, 2010, 70, 7455-7464.	0.9	118
24	A Phase I Trial to Determine the Optimal Biological Dose of Celecoxib when Combined with Erlotinib in Advanced Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2006, 12, 3381-3388.	7.0	111
25	Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD1480. Cancer Research, 2011, 71, 6601-6610.	0.9	109
26	Targeting STAT3 in Adoptively Transferred T Cells Promotes Their In Vivo Expansion and Antitumor Effects. Cancer Research, 2010, 70, 9599-9610.	0.9	108
27	Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. Journal of Thoracic Oncology, 2020, 15, 404-415.	1.1	102
28	STAT3: A Target to Enhance Antitumor Immune Response. Current Topics in Microbiology and Immunology, 2010, 344, 41-59.	1.1	97
29	¹⁸F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor Receptor Inhibitor Erlotinib. Journal of Nuclear Medicine, 2011, 52, 1684-1689.	5.0	94
30	A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. Cancer Discovery, 2019, 9, 384-395.	9.4	88
31	A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.. Journal of Clinical Oncology, 2018, 36, 102-102.	1.6	87
32	Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Nonâ€“Small-Cell Lung Cancer Previously Treated With Immunotherapyâ€”Lung-MAP S1800A. Journal of Clinical Oncology, 2022, 40, 2295-2307.	1.6	84
33	Intrapulmonary Administration of CCL21 Gene-Modified Dendritic Cells Reduces Tumor Burden in Spontaneous Murine Bronchoalveolar Cell Carcinoma. Cancer Research, 2006, 66, 3205-3213.	0.9	82
34	The Potential and Rationale for COX-2 Inhibitors in Lung Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2006, 6, 209-220.	1.7	77
35	A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma. Lung Cancer, 2019, 138, 124-130.	2.0	77
36	Targeted Therapies for Nonâ€“Small Cell Lung Cancer: An Evolving Landscape. Molecular Cancer Therapeutics, 2010, 9, 1931-1944.	4.1	74

#	Article	IF	Citations
37	JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, 9009-9009.	1.6	74
38	Cyclooxygenase 2 Inhibition Promotes IFN-Î³-Dependent Enhancement of Antitumor Responses. Journal of Immunology, 2005, 175, 813-819.	0.8	73
39	Inflammation and lung carcinogenesis: applying findings in prevention and treatment. Expert Review of Anticancer Therapy, 2007, 7, 1405-1421.	2.4	71
40	Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations. Clinical Cancer Research, 2019, 25, 5832-5842.	7.0	64
41	A Multiparametric Serum Kallikrein Panel for Diagnosis of Nonâ€“Small Cell Lung Carcinoma. Clinical Cancer Research, 2008, 14, 1355-1362.	7.0	63
42	Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Nonâ€“Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). Journal of Clinical Oncology, 2017, 35, 2184-2192.	1.6	63
43	Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Nonâ€“Small Cell Lung Cancer Who Previously Progressed on Erlotinib. Clinical Cancer Research, 2015, 21, 4321-4326.	7.0	59
44	Tumor Response to Combination Celecoxib and Erlotinib Therapy in Non-small Cell Lung Cancer Is Associated with a Low Baseline Matrix Metalloproteinase-9 and a Decline in Serum-Soluble E-Cadherin. Journal of Thoracic Oncology, 2008, 3, 117-124.	1.1	56
45	Phase 1b Study of Motesanib, an Oral Angiogenesis Inhibitor, in Combination with Carboplatin/Paclitaxel and/or Panitumumab for the Treatment of Advanced Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2010, 16, 279-290.	7.0	56
46	PGE(2) contributes to TGF-beta induced T regulatory cell function in human non-small cell lung cancer. American Journal of Translational Research (discontinued), 2010, 2, 356-67.	0.0	52
47	Inflammation, Epithelial to Mesenchymal Transition, and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance. Journal of Thoracic Oncology, 2008, 3, 107-110.	1.1	50
48	Chemoprevention Strategies with Cyclooxygenase-2 Inhibitors for Lung Cancer. Clinical Lung Cancer, 2005, 7, 30-39.	2.6	42
49	The Role of Targeting Mammalian Target of Rapamycin in Lung Cancer. Clinical Lung Cancer, 2008, 9, 340-345.	2.6	42
50	PGE2confers survivin-dependent apoptosis resistance in human monocyte-derived dendritic cells. Journal of Leukocyte Biology, 2005, 78, 555-564.	3.3	40
51	A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With AdvancedÂNonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 556-566.	1.1	40
52	PGE2-Driven Expression of c-Myc and OncomiR-17-92 Contributes to Apoptosis Resistance in NSCLC. Molecular Cancer Research, 2014, 12, 765-774.	3.4	37
53	An Interdisciplinary Care Approach for Integration of Palliative Care in Lung Cancer. Clinical Lung Cancer, 2008, 9, 352-360.	2.6	36
54	Longitudinal Changes in Function, Symptom Burden, and Quality of Life in Patients with Early-Stage Lung Cancer. Annals of Surgical Oncology, 2013, 20, 1788-1797.	1.5	35

#	Article	IF	Citations
55	CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer. BMC Cancer, 2009, 9, 213.	2.6	34
56	The impact of lung cancer surgery on quality of life trajectories in patients and family caregivers. Lung Cancer, 2016, 101, 35-39.	2.0	33
57	Long-Term Effect of an Interdisciplinary Supportive Care Intervention for Lung Cancer Survivors After Surgical Procedures. Annals of Thoracic Surgery, 2016, 101, 495-503.	1.3	33
58	Randomized phase 2 trial of erlotinib in combination with highâ€dose celecoxib or placebo in patients with advanced nonâ€small cell lung cancer. Cancer, 2015, 121, 3298-3306.	4.1	32
59	A Multimedia Self-management Intervention to Prepare Cancer Patients and Family Caregivers for Lung Surgery and Postoperative Recovery. Clinical Lung Cancer, 2017, 18, e151-e159.	2.6	32
60	Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts).. Journal of Clinical Oncology, 2015, 33, 8001-8001.	1.6	31
61	Expression of CXCR3 on Mononuclear Cells and CXCR3 Ligands in Patients With Metastatic Renal Cell Carcinoma in Response to Systemic IL-2 Therapy. Journal of Immunotherapy, 2007, 30, 417-424.	2.4	30
62	Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.8	30
63	Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer. Cancer Research, 2021, 81, 6273-6280.	0.9	30
64	Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab. Targeted Oncology, 2015, 10, 65-76.	3.6	29
65	Role of immunotherapy and co-mutations on KRAS-mutant non- small cell lung cancer survival. Journal of Thoracic Disease, 2020, 12, 5086-5095.	1.4	29
66	Non-Small Cell Lung Cancer in the Elderly: Defining Treatment Options. Seminars in Oncology, 2008, 35, 590-596.	2.2	28
67	Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.. Journal of Clinical Oncology, 2013, 31, 8028-8028.	1.6	28
68	The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA. Clinical Cancer Research, 2018, 24, 6053-6065.	7.0	27
69	A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, 8009-8009.	1.6	27
70	Predictors of finding benefit after lung cancer diagnosis. Psycho-Oncology, 2012, 21, 365-373.	2.3	26
71	Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer. Chest, 2021, 160, 1095-1107.	0.8	23
72	Chemokines as therapeutic targets in renal cell carcinoma. Expert Review of Anticancer Therapy, 2008, 8, 887-893.	2.4	22

#	Article	IF	Citations
73	Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.. Journal of Clinical Oncology, 2013, 31, 8027-8027.	1.6	22
74	Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio. Lung Cancer, 2019, 133, 136-143.	2.0	21
75	Preparing Cancer Patients and Family Caregivers for Lung Surgery: Development of a Multimedia Self-Management Intervention. Journal of Cancer Education, 2018, 33, 557-563.	1.3	20
76	Biomarkerâ€based phase I doseâ€escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer. Cancer, 2011, 117, 809-818.	4.1	19
77	Urine test for EGFR analysis in patients with non-small cell lung cancer. Journal of Thoracic Disease, 2017, 9, S1323-S1331.	1.4	19
78	Randomized Phase II Trial of Concurrent Versus Sequential Bortezomib Plus Docetaxel in Advanced Nonâ€“Small-Cell Lung Cancer: A California Cancer Consortium Trial. Clinical Lung Cancer, 2011, 12, 33-37.	2.6	18
79	Phase II trial of XL184 (cabozantinib) plus erlotinib in patients (pts) with advanced EGFR-mutant non-small cell lung cancer (NSCLC) with progressive disease (PD) on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy: A California Cancer Consortium phase II trial (NCI 9303).. Journal of Clinical Oncology, 2014, 32, 8014-8014.	1.6	18
80	Two parallel randomized phase II studies of selumetinib (S) and erlotinib (E) in advanced non-small cell lung cancer selected by KRAS mutations.. Journal of Clinical Oncology, 2013, 31, 8026-8026.	1.6	17
81	Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Nonâ€“Small Cell Lung Cancer. Clinical Lung Cancer, 2022, 23, 72-81.	2.6	17
82	CRESTONE: Initial efficacy and safety of seribantumab in solid tumors harboring NRG1 fusions.. Journal of Clinical Oncology, 2022, 40, 3006-3006.	1.6	17
83	Real-World Pseudoprogression: an Uncommon Phenomenon. Journal of Thoracic Oncology, 2018, 13, 880-882.	1.1	15
84	Myeloid Clusters Are Associated with a Pro-Metastatic Environment and Poor Prognosis in Smoking-Related Early Stage Non-Small Cell Lung Cancer. PLoS ONE, 2013, 8, e65121.	2.5	15
85	Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer. American Journal of Translational Research (discontinued), 2013, 5, 481-96.	0.0	13
86	Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma. Cancer Biology and Therapy, 2018, 19, 1023-1032.	3.4	12
87	Duration of Targeted Therapy in Patients With Advanced Nonâ€“small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis. Clinical Lung Cancer, 2020, 21, 545-552.e1.	2.6	11
88	Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. JTO Clinical and Research Reports, 2021, 2, 100114.	1.1	11
89	Bortezomib for Patients with Advanced-Stage Bronchioloalveolar Carcinoma: A California Cancer Consortium Phase II Study (NCI 7003). Journal of Thoracic Oncology, 2011, 6, 1741-1745.	1.1	10
90	A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2022, 89, 105-115.	2.3	10

#	Article	IF	Citations
91	Management of non-small-cell lung cancer in the older adult. Maturitas, 2011, 68, 311-321.	2.4	9
92	Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients. Cancers, 2021, 13, 2776.	3.7	9
93	A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry. Journal of Thoracic Oncology, 2022, 17, 661-674.	1.1	9
94	Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer. Cancer Letters, 2012, 321, 101-109.	7.2	8
95	Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing. Oncologist, 2018, 23, 776-781.	3.7	8
96	EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Nonâ€“Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor. JCO Precision Oncology, 2018, 2, 1-13.	3.0	8
97	Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors. Lung Cancer, 2020, 146, 174-181.	2.0	8
98	Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer. JCO Oncology Practice, 2021, 17, e257-e265.	2.9	8
99	Combination of Immunotherapy and Antiangiogenic Therapy in Cancerâ€”a Rational Approach. Journal of Thoracic Oncology, 2021, 16, 178-182.	1.1	8
100	Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878). Clinical Lung Cancer, 2021, 22, 541-548.	2.6	8
101	The Association between Polluted Neighborhoods and TP53-Mutated Nonâ€“Small Cell Lung Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1498-1505.	2.5	8
102	Recall of Genomic Testing Results Among Patients with Cancer. Oncologist, 2021, 26, e2302-e2305.	3.7	8
103	CCL21 Chemokine Therapy for Lung Cancer. International Trends in Immunity, 2013, 1, 10-15.	0.4	8
104	Intraventricular Chemotherapy for Leptomeningeal Carcinomatosis from Lung Cancer: A Feasible and Beneficial Treatment Option?. Journal of Thoracic Oncology, 2013, 8, 523-524.	1.1	7
105	Precision medicine and actionable alterations in lung cancer: A single institution experience. PLoS ONE, 2020, 15, e0228188.	2.5	7
106	Phase II study of the AKT inhibitor MK-2206 plus erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC) who progressed on prior erlotinib: A California Cancer Consortium Phase II trial (NCI 8698).. Journal of Clinical Oncology, 2014, 32, 8015-8015.	1.6	7
107	Biomarker analysis of a phase II trial of cabozantinib and erlotinib in patients (pts) with EGFR-mutant NSCLC with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance: A California Cancer Consortium Phase II Trial (NCI 9303).. Journal of Clinical Oncology, 2015, 33, 8087-8087.	1.6	7
108	Symptomology following mRNA vaccination against SARS-CoV-2. Preventive Medicine, 2021, 153, 106860.	3.4	7

#	Article	IF	Citations
109	Population pharmacokinetic and exposureâ€response analyses from ALTAâ€1L: Modelâ€based analyses supporting the brigatinib dose in ALKâ€positive NSCLC. Clinical and Translational Science, 2022, 15, 1143-1154.	3.1	7
110	Consistency of a two clinical site sample collection: A proteomics study. Proteomics - Clinical Applications, 2010, 4, 726-738.	1.6	6
111	Anaplastic Lymphoma Kinase (ALK)-positive Tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 337-344.	1.3	6
112	Molecular Targets Beyond the Big 3. Thoracic Surgery Clinics, 2020, 30, 157-164.	1.0	6
113	A Lung Cancer Screening Education Program Impacts both Referral Rates and Provider and Medical Assistant Knowledge at Two Federally Qualified Health Centers. Clinical Lung Cancer, 2021, , .	2.6	6
114	Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.. Journal of Clinical Oncology, 2022, 40, 9014-9014.	1.6	6
115	Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced nonâ€“small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A.. Journal of Clinical Oncology, 2022, 40, 9004-9004.	1.6	6
116	A phase 1/2 study of BLU-945 in patients with common activating EGFR-mutant nonâ€“small cell lung cancer (NSCLC): SYMPHONY trial in progress.. Journal of Clinical Oncology, 2022, 40, TPS9156-TPS9156.	1.6	6
117	Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies. Open Forum Infectious Diseases, 2022, 9, .	0.9	5
118	A phase 1/2 study of the highly selective EGFR inhibitor, BLU-701, in patients with EGFR-mutant nonâ€“small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2022, 40, TPS9142-TPS9142.	1.6	5
119	Is benefit of maintenance therapy for NSCLC best defined by progression-free survival?. Lancet Oncology, The, 2012, 13, 435-436.	10.7	4
120	Immunotherapy in Advanced Non-Small Cell Lung Cancer. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 400-408.	2.1	4
121	Genomic instability as a major mechanism for acquired resistance to EGFR tyrosine kinase inhibitors in cancer. Protein and Cell, 2022, 13, 82-89.	11.0	4
122	Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data. Drugs - Real World Outcomes, 2022, 9, 333-345.	1.6	4
123	Multiarm, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling.. Journal of Clinical Oncology, 2014, 32, TPS8120-TPS8120.	1.6	3
124	Combination chemotherapy for older adults with advanced non-small-cell lung cancer. Lancet, The, 2011, 378, 1055-1057.	13.7	2
125	Phosphatidylinositol-3-Kinase Pathway. Journal of Thoracic Oncology, 2012, 7, S383-S384.	1.1	2
126	Future of ALK inhibition in non-small-cell lung cancer. Lancet Oncology, The, 2014, 15, 1047-1049.	10.7	2

#	Article	IF	Citations
127	Nonâ€“Small Cell Lung Cancer Patient Preferences for First-Line Treatment: A Discrete Choice Experiment. MDM Policy and Practice, 2020, 5, 238146832092220.	0.9	2
128	CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusionsâ€”A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210).. Journal of Clinical Oncology, 2021, 39, TPS449-TPS449.	1.6	2
129	Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors. Cancers, 2021, 13, 2653.	3.7	2
130	Immune Checkpoint and Anti-Angiogenic Antibodies for the Treatment of Non-Small Cell Lung Cancer in the European Union and United States. Pharmaceutics, 2021, 13, 912.	4.5	2
131	Population pharmacokinetic (PK) and exposure-response analyses from the pivotal ALTA-1L study: Model-based analyses supporting the brigatinib dose in patients with anaplastic lymphoma kinase (ALK)â€“positive nonâ€“small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, e21725-e21725.	1.6	2
132	A phase II randomized study of telaglenastat, a glutaminase (GLS) inhibitor, versus placebo, in combination with pembrolizumab (Pembro) and chemotherapy as first-line treatment for KEAP1/NRF2-mutated non-squamous metastatic non-small cell lung cancer (mNSCLC).. Journal of Clinical Oncology, 2020, 38, TPS9627-TPS9627.	1.6	2
133	Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer. Future Oncology, 2022, 18, 2499-2510.	2.4	2
134	Successful biosimilar adoption in oncology: strategic approach to system standardization.. Journal of Clinical Oncology, 2022, 40, e18605-e18605.	1.6	2
135	Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinaseâ€“positive nonâ€“small cell lung cancer using data from ALEX and final results from ALTA-1L. Current Medical Research and Opinion, 2022, 38, 1587-1593.	1.9	2
136	City of hope cancer center hematologyâ€“oncology fellowship and hematopoietic stem cell transplantation fellowship. American Journal of Hematology, 2011, 86, 197-198.	4.1	1
137	A 75-Year-Old Man With Progressive Bronchioalveolar Carcinoma. Seminars in Oncology, 2013, 40, e1-e8.	2.2	1
138	Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations. Future Science OA, 2021, 7, FSO662.	1.9	1
139	Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with a checkpoint inhibitor: Toxicity update (Lung-MAP) Tj ETQq1 1 0.784314 rgBT /Overlo	7.8	
140	Cancer Screening Practices Among Healthcare Workers During the COVID-19 Pandemic. Frontiers in Public Health, 2022, 10, 801805.	2.7	1
141	Summary of Selected Presentations from the 8th Annual Targeted Therapy in Lung Cancer Symposium. Journal of Thoracic Oncology, 2009, 4, 930-935.	1.1	0
142	Novel Mechanisms and Targets; Miscellaneous Agents. Journal of Thoracic Oncology, 2011, 6, S1812-S1814.	1.1	0
143	Clinical outcomes for plasma-based comprehensive genomic profiling versus tissue testing in advanced lung adenocarcinoma.. Journal of Clinical Oncology, 2021, 39, 9027-9027.	1.6	0
144	Chemokines in Renal Cell Carcinoma: Implications for Tumor Angiogenesis and Metastasis. , 2009, , 249-265.		0

#	Article	IF	Citations
145	Characterizing and Modulating the Tumor Microenvironment in Renal Cell Carcinoma: Potential Therapeutic Strategies. , 2012, , 239-252.		0
146	Cancers of the Respiratory System. , 2014, , 557-574.		0
147	Interdisciplinary palliative care for patients with lung cancer.. Journal of Clinical Oncology, 2015, 33, 130-130.	1.6	0
148	The association between immune-related adverse events and efficacy outcomes with consolidation pembrolizumab after chemoradiation in patients with stage III NSCLC: an analysis from HCRN LUN 14-179.. Journal of Clinical Oncology, 2020, 38, 9032-9032.	1.6	0
149	QIM22-198: Optimizing a Systemic Platform to Standardize Oncologic Biosimilars Utilization at Cedars-Sinai Medical Center (CSMC). Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, QIM22-198.	4.9	0
150	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0
151	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0
152	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0
153	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0
154	Characterization of MET exon 14 skipping alterations (METex14) in nonâ€“small cell lung cancer (NSCLC) using whole transcriptome sequencing (WTS).. Journal of Clinical Oncology, 2022, 40, 9122-9122.	1.6	0
155	Clinical application of precision medicine among oncologists: A case study in RET-targeted therapy.. Journal of Clinical Oncology, 2022, 40, e18705-e18705.	1.6	0